000141169 001__ 141169
000141169 005__ 20240229112523.0
000141169 0247_ $$2doi$$a10.1007/s00330-018-5751-1
000141169 0247_ $$2pmid$$apmid:30327861
000141169 0247_ $$2ISSN$$a0938-7994
000141169 0247_ $$2ISSN$$a1432-1084
000141169 0247_ $$2ISSN$$a1613-3749
000141169 0247_ $$2ISSN$$a1613-3757
000141169 0247_ $$2altmetric$$aaltmetric:51969279
000141169 037__ $$aDKFZ-2018-01696
000141169 041__ $$aeng
000141169 082__ $$a610
000141169 1001_ $$0P:(DE-He78)ea098e4d78abeb63afaf8c25ec6d6d93$$aBonekamp, David$$b0$$eFirst author
000141169 245__ $$aHistopathological to multiparametric MRI spatial mapping of extended systematic sextant and MR/TRUS-fusion-targeted biopsy of the prostate.
000141169 260__ $$aHeidelberg$$bSpringer$$c2019
000141169 3367_ $$2DRIVER$$aarticle
000141169 3367_ $$2DataCite$$aOutput Types/Journal article
000141169 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1576227246_13910
000141169 3367_ $$2BibTeX$$aARTICLE
000141169 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000141169 3367_ $$00$$2EndNote$$aJournal Article
000141169 520__ $$aMRI has limited ability to detect multifocal disease or the full extent of prostate involvement with clinically significant prostate cancer (sPC). We compare the spatial co-localization at sextant resolution of MRI lesions and histopathological mapping by combined targeted and extended systematic biopsies.Sextants were mapped for sPC (ISUP group ≥ 2) by 24-core transperineal systematic biopsies in 316 patients with suspicion for sPC and by MR lesions of PI-RADS score of ≥ 3. The gold standard is combined systematic (median 23 cores) and targeted biopsies.Of 316 men, 121 (38%) harbored sPC. Of these 121 patients, 4 (3%) had a negative MRI. MRI correctly identified 117/121 (97%) patients with sPC. In these patients, mpMRI missed no additional sPC in 96 (82%), while MRI-negative sPC lesions were present in 21 patients (18%). Of 1896 sextants, 379 (20%) harbored sPC. MR-positive sextants contained sPC in 26% (337/1275), compared to 7% (42/621) in MR-negative sextants. On a patient basis, sensitivity was 0.97, specificity 0.22, positive predictive value 0.43, and negative predictive value 0.91. On a sextant basis, sensitivity was 0.73, specificity 0.38, positive predictive value 0.26, and negative predictive value 0.93.MpMRI mapping agreed well with histopathology with, at the observed sPC prevalence and on a patient basis, excellent sensitivity and negative predictive value, and acceptable specificity and positive predictive value for sPC. However, 18% of sPC was outside the mpMRI mapped region, quantifying limitations of MRI for complete localization of disease extent.• Currently, exclusive MRI mapping of the prostate for focal treatment planning cannot be recommended, as significant prostate cancer may remain untreated in a substantial number of cases. • At the observed sPC prevalence and on a patient basis, mpMRI has excellent sensitivity and NPV, and acceptable specificity and PPV for detection of prostate cancer, supporting its use to detect suspicious lesions before biopsy. • Despite the excellent global performance, 18% of sPC was outside the mpMRI mapped region even when a security margin of 10 mm was considered, indicating that prostate MRI has limited ability to completely map all cancer foci within the prostate.
000141169 536__ $$0G:(DE-HGF)POF3-315$$a315 - Imaging and radiooncology (POF3-315)$$cPOF3-315$$fPOF III$$x0
000141169 588__ $$aDataset connected to CrossRef, PubMed,
000141169 7001_ $$0P:(DE-HGF)0$$aSchelb, Patrick$$b1
000141169 7001_ $$0P:(DE-He78)1042737c83ba70ec508bdd99f0096864$$aWiesenfarth, Manuel$$b2
000141169 7001_ $$0P:(DE-He78)59dfdd0ee0a7f0db81535f0781a3a6d6$$aKuder, Tristan Anselm$$b3
000141169 7001_ $$0P:(DE-He78)3afd7ad05414293928330064c4955805$$aDeister, Fenja$$b4$$udkfz
000141169 7001_ $$aStenzinger, Albrecht$$b5
000141169 7001_ $$aNyarangi-Dix, Joanne$$b6
000141169 7001_ $$0P:(DE-He78)3d11afed6b72f876ad1bba9418e30dac$$aRöthke, Matthias$$b7
000141169 7001_ $$aHohenfellner, Markus$$b8
000141169 7001_ $$0P:(DE-He78)3d04c8fee58c9ab71f62ff80d06b6fec$$aSchlemmer, Heinz-Peter$$b9
000141169 7001_ $$0P:(DE-He78)79897f8897ff77676549d9895258a0f2$$aRadtke, Jan Philipp$$b10$$eLast author
000141169 773__ $$0PERI:(DE-600)1472718-3$$a10.1007/s00330-018-5751-1$$n4$$p1820-1830$$tEuropean radiology$$v29$$x1432-1084$$y2019
000141169 909CO $$ooai:inrepo02.dkfz.de:141169$$pVDB
000141169 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)ea098e4d78abeb63afaf8c25ec6d6d93$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000141169 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000141169 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)1042737c83ba70ec508bdd99f0096864$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000141169 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)59dfdd0ee0a7f0db81535f0781a3a6d6$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000141169 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)3afd7ad05414293928330064c4955805$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000141169 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)3d11afed6b72f876ad1bba9418e30dac$$aDeutsches Krebsforschungszentrum$$b7$$kDKFZ
000141169 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)3d04c8fee58c9ab71f62ff80d06b6fec$$aDeutsches Krebsforschungszentrum$$b9$$kDKFZ
000141169 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)79897f8897ff77676549d9895258a0f2$$aDeutsches Krebsforschungszentrum$$b10$$kDKFZ
000141169 9131_ $$0G:(DE-HGF)POF3-315$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vImaging and radiooncology$$x0
000141169 9141_ $$y2019
000141169 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz
000141169 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bEUR RADIOL : 2017
000141169 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000141169 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000141169 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search
000141169 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC
000141169 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List
000141169 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000141169 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000141169 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000141169 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine
000141169 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5
000141169 9201_ $$0I:(DE-He78)E010-20160331$$kE010$$lRadiologie$$x0
000141169 9201_ $$0I:(DE-He78)C060-20160331$$kC060$$lBiostatistik$$x1
000141169 9201_ $$0I:(DE-He78)E020-20160331$$kE020$$lMedizinische Physik in der Radiologie$$x2
000141169 980__ $$ajournal
000141169 980__ $$aVDB
000141169 980__ $$aI:(DE-He78)E010-20160331
000141169 980__ $$aI:(DE-He78)C060-20160331
000141169 980__ $$aI:(DE-He78)E020-20160331
000141169 980__ $$aUNRESTRICTED